Kun Liu1, Qiang Tang2, Xinyuan Zhu2, Xinchun Yang3. 1. Heart Center of Beijing Chao-Yang Hospital Affiliated Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China; Department of Cardiology, Peking University Shougang Hospital, Shijingshan District, Beijing 100144, China. 2. Department of Cardiology, Peking University Shougang Hospital, Shijingshan District, Beijing 100144, China. 3. Heart Center of Beijing Chao-Yang Hospital Affiliated Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China. Electronic address: yangxinchun2016@163.com.
Abstract
BACKGROUND: IL-37 emerges as a natural suppressor of inflammatory responses. The potential role of IL-37 in the pathology of atherosclerosis is unclear. The purpose of this study was to assess IL-37 profile in acute coronary syndrome (ACS) and the prognostic role of this cytokine in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). METHODS: In a case-control study, we prospectively enrolled 216 patients undergoing the first coronary angiography, which consisted of 5 groups: normal (n=57), stable angina (SAP, n=36), unstable angina (UAP, n=42), non-STEMI (n=36), STEMI (n=45). Plasma IL-37, IL-6 and serum amyloid A (SAA) were measured using a commercially ELISA kit. Besides, in a prospective cohort study, 125 patients with STEMI of onset <12h undergoing PPCI were enrolled and divided into 2 groups according to the concentrations of IL-37 (<341.1pg/ml or ≥341.1pg/ml). In-hospital major adverse cardiac event (MACE) including nonfatal myocardial infarction (MI), target lesion revascularization, acute heart failure, and cardiac death were estimated for prognosis. RESULTS: IL-37 was gradually increased in accordance with the severity of coronary artery disease. The circulating concentration of IL-37 was remarkably higher in the ACS patients than in either of the normal or SAP patients (p<0.05), and especially higher in the AMI patients including STEMI and non-STEMI than in the angina pectoris subjects no matter SAP or UAP (p<0.05). There was no statistical difference of IL-37 between normal and SAP patients, STEMI and non-STEMI patients (p>0.05). The trend of the change of IL-37 was consistent with that of SAA or IL-6. A higher circulating concentration of IL-37 before PPCI was accompanied with the decreased LVEF and the increased NT-proBNP concentrations, and independently predictive of in-hospital MACE rate in patients with STEMI undergoing PPCI (OR=3.652, 95% CI=1.113-11.983, p<0.05). CONCLUSIONS: We demonstrated the IL-37 profile in patients with acute coronary syndrome and the increased IL-37 concentration was associated with a worse clinical in-hospital outcome in STEMI patients undergoing PPCI.
BACKGROUND:IL-37 emerges as a natural suppressor of inflammatory responses. The potential role of IL-37 in the pathology of atherosclerosis is unclear. The purpose of this study was to assess IL-37 profile in acute coronary syndrome (ACS) and the prognostic role of this cytokine in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). METHODS: In a case-control study, we prospectively enrolled 216 patients undergoing the first coronary angiography, which consisted of 5 groups: normal (n=57), stable angina (SAP, n=36), unstable angina (UAP, n=42), non-STEMI (n=36), STEMI (n=45). Plasma IL-37, IL-6 and serum amyloid A (SAA) were measured using a commercially ELISA kit. Besides, in a prospective cohort study, 125 patients with STEMI of onset <12h undergoing PPCI were enrolled and divided into 2 groups according to the concentrations of IL-37 (<341.1pg/ml or ≥341.1pg/ml). In-hospital major adverse cardiac event (MACE) including nonfatal myocardial infarction (MI), target lesion revascularization, acute heart failure, and cardiac death were estimated for prognosis. RESULTS:IL-37 was gradually increased in accordance with the severity of coronary artery disease. The circulating concentration of IL-37 was remarkably higher in the ACS patients than in either of the normal or SAPpatients (p<0.05), and especially higher in the AMI patients including STEMI and non-STEMI than in the angina pectoris subjects no matter SAP or UAP (p<0.05). There was no statistical difference of IL-37 between normal and SAPpatients, STEMI and non-STEMI patients (p>0.05). The trend of the change of IL-37 was consistent with that of SAA or IL-6. A higher circulating concentration of IL-37 before PPCI was accompanied with the decreased LVEF and the increased NT-proBNP concentrations, and independently predictive of in-hospital MACE rate in patients with STEMI undergoing PPCI (OR=3.652, 95% CI=1.113-11.983, p<0.05). CONCLUSIONS: We demonstrated the IL-37 profile in patients with acute coronary syndrome and the increased IL-37 concentration was associated with a worse clinical in-hospital outcome in STEMI patients undergoing PPCI.